AbbVie and Ichnos Glenmark Innovation Forge Strategic Partnership for Promising Trispecific Antibody ISB 2001
North Chicago, IL and Lausanne, Switzerland – July 10, 2025 – In a significant development for the oncology treatment landscape, AbbVie (NYSE: ABBV) and Ichnos Glenmark Innovation (IGI) today announced an exclusive global licensing agreement for ISB 2001. This innovative molecule is a first-in-class trispecific antibody designed to target CD38, BCMA, and CD3 simultaneously, holding considerable promise for patients battling various hematologic malignancies.
This strategic collaboration brings together AbbVie’s extensive expertise in oncology research, development, and commercialization with IGI’s pioneering work in antibody engineering and bispecific and trispecific antibody development. The agreement grants AbbVie exclusive worldwide rights to develop, manufacture, and commercialize ISB 2001.
ISB 2001 represents a novel approach to harnessing the power of the immune system to fight cancer. By engaging CD3 on T-cells, BCMA (B-cell maturation antigen) on cancer cells, and CD38 – a target found on various plasma cells, including malignant plasma cells in multiple myeloma and certain lymphomas – this trispecific antibody aims to orchestrate a potent and targeted anti-tumor response. The simultaneous targeting of these three molecules is designed to enhance T-cell activation and infiltration into tumor sites, leading to more effective cancer cell destruction.
The potential of ISB 2001 to address unmet needs in hematologic cancers is a key driver behind this partnership. Multiple myeloma, a particularly aggressive form of blood cancer, and other plasma cell disorders are areas where novel therapeutic strategies are continually sought. AbbVie’s established presence and deep understanding in these therapeutic areas will be instrumental in advancing ISB 2001 through clinical trials and making it accessible to patients.
Under the terms of the agreement, IGI will receive an upfront payment and is eligible to receive potential future milestone payments, as well as royalties on net sales of ISB 2001. Further details of the financial arrangements have not been disclosed.
This collaboration underscores AbbVie’s commitment to expanding its oncology pipeline with cutting-edge science and novel therapeutic modalities. By joining forces with IGI, AbbVie is strategically positioning itself to address significant challenges in cancer care and potentially transform the treatment paradigms for patients with hematologic malignancies. The companies are enthusiastic about the prospect of advancing ISB 2001, with the shared goal of delivering innovative solutions to those in need.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
www.prnewswire.com published ‘AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody’ at 2025-07-10 11:30. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.